These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

164 related items for PubMed ID: 35662814

  • 41. A new strategy of desensitization in mucopolysaccharidosis type II disease treated with idursulfase therapy: A case report and review of the literature.
    Gragnaniello V, Carraro S, Rubert L, Gueraldi D, Cazzorla C, Massa P, Zanconato S, Burlina AB.
    Mol Genet Metab Rep; 2022 Jun; 31():100878. PubMed ID: 35782619
    [Abstract] [Full Text] [Related]

  • 42. Therapeutic Options for Mucopolysaccharidosis II (Hunter Disease).
    Kubaski F, Vairo F, Baldo G, de Oliveira Poswar F, Corte AD, Giugliani R.
    Curr Pharm Des; 2020 Jun; 26(40):5100-5109. PubMed ID: 33138761
    [Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45. Detection of mucopolysaccharidosis type II by measurement of iduronate-2-sulfatase in dried blood spots and plasma samples.
    Dean CJ, Bockmann MR, Hopwood JJ, Brooks DA, Meikle PJ.
    Clin Chem; 2006 Apr; 52(4):643-9. PubMed ID: 16497940
    [Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47. Review of the use of idursulfase in the treatment of mucopolysaccharidosis II.
    Burrow TA, Leslie ND.
    Biologics; 2008 Jun; 2(2):311-20. PubMed ID: 19707363
    [Abstract] [Full Text] [Related]

  • 48. Dose-Dependent Prevention of Metabolic and Neurologic Disease in Murine MPS II by ZFN-Mediated In Vivo Genome Editing.
    Laoharawee K, DeKelver RC, Podetz-Pedersen KM, Rohde M, Sproul S, Nguyen HO, Nguyen T, St Martin SJ, Ou L, Tom S, Radeke R, Meyer KE, Holmes MC, Whitley CB, Wechsler T, McIvor RS.
    Mol Ther; 2018 Apr 04; 26(4):1127-1136. PubMed ID: 29580682
    [Abstract] [Full Text] [Related]

  • 49. Extension of the molecular analysis to the promoter region of the iduronate 2-sulfatase gene reveals genomic alterations in mucopolysaccharidosis type II patients with normal coding sequence.
    Brusius-Facchin AC, Abrahão L, Schwartz IV, Lourenço CM, Santos ES, Zanetti A, Tomanin R, Scarpa M, Giugliani R, Leistner-Segal S.
    Gene; 2013 Sep 10; 526(2):150-4. PubMed ID: 23707223
    [Abstract] [Full Text] [Related]

  • 50. Changes in glycogen and glycosaminoglycan levels in hepatocytes of iduronate-2-sulfatase knockout mice before and after recombinant iduronate-2-sulfatase supplementation.
    Lee JH, Choe YH, Kim SJ, Paik KH, Jin DK.
    Yonsei Med J; 2011 Mar 10; 52(2):263-7. PubMed ID: 21319344
    [Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52. Expression in CHO cells and pharmacokinetics and brain uptake in the Rhesus monkey of an IgG-iduronate-2-sulfatase fusion protein.
    Lu JZ, Boado RJ, Hui EK, Zhou QH, Pardridge WM.
    Biotechnol Bioeng; 2011 Aug 10; 108(8):1954-64. PubMed ID: 21351076
    [Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54. Caprine mucopolysaccharidosis IIID: fetal and neonatal brain and liver glycosaminoglycan and morphological perturbations.
    Jones MZ, Alroy J, Downs-Kelly E, Lucas RE, Kraemer SA, Cavanagh KT, King B, Hopwood JJ.
    J Mol Neurosci; 2004 Aug 10; 24(2):277-91. PubMed ID: 15456941
    [Abstract] [Full Text] [Related]

  • 55. Effectiveness of Early Hematopoietic Stem Cell Transplantation in Preventing Neurocognitive Decline in Mucopolysaccharidosis Type II: A Case Series.
    Selvanathan A, Ellaway C, Wilson C, Owens P, Shaw PJ, Bhattacharya K.
    JIMD Rep; 2018 Aug 10; 41():81-89. PubMed ID: 29671225
    [Abstract] [Full Text] [Related]

  • 56. Autophagy in the Central Nervous System and Effects of Chloroquine in Mucopolysaccharidosis Type II Mice.
    Maeda M, Seto T, Kadono C, Morimoto H, Kida S, Suga M, Nakamura M, Kataoka Y, Hamazaki T, Shintaku H.
    Int J Mol Sci; 2019 Nov 20; 20(23):. PubMed ID: 31757021
    [Abstract] [Full Text] [Related]

  • 57. Low-dose, continuous enzyme replacement therapy ameliorates brain pathology in the neurodegenerative lysosomal disorder mucopolysaccharidosis type IIIA.
    King B, Hassiotis S, Rozaklis T, Beard H, Trim PJ, Snel MF, Hopwood JJ, Hemsley KM.
    J Neurochem; 2016 May 20; 137(3):409-22. PubMed ID: 26762778
    [Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59. Biodistribution of Idursulfase Formulated for Intrathecal Use (Idursulfase-IT) in Cynomolgus Monkeys after Intrathecal Lumbar Administration.
    Chung JK, Brown E, Crooker B, Palmieri KJ, McCauley TG.
    PLoS One; 2016 May 20; 11(10):e0164765. PubMed ID: 27764180
    [Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.